340774-26-7

Basic information

• Product Name: (1-cyclopropyl-Methanoyl)-diMethylaMino-acrylic acid Methyl ester
• Synonyms: (1-cyclopropyl-Methanoyl)-diMethylaMino-acrylic acid Methyl ester;2-Cyclopropylcarbonyl-3-diMethylaMinoacrylic Acid Methyl Ester;(E)-methyl 2-(cyclopropanecarbonyl)-3-(dimethylamino)acrylate
• CAS NO: 340774-26-7
• Molecular Formula: C₁₀H₁₅NO₃
• Molecular Weight: 197.231
• Product Categories: Miscellaneous Reagents, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 340774-26-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Solubility: DCM, Ethyl Acetate
• CAS DataBase Reference: (1-cyclopropyl-Methanoyl)-diMethylaMino-acrylic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (1-cyclopropyl-Methanoyl)-diMethylaMino-acrylic acid Methyl ester(340774-26-7)
• EPA Substance Registry System: (1-cyclopropyl-Methanoyl)-diMethylaMino-acrylic acid Methyl ester(340774-26-7)

Safety Data

• Hazardous Substances Data: 340774-26-7(Hazardous Substances Data)

Usage

Description

(1-cyclopropyl-methanoyl)-dimethylamino-acrylic acid methyl ester, also known as 2-Cyclopropylcarbonyl-3-dimethylaminoacrylic Acid Methyl Ester, is an organic compound that serves as a crucial intermediate in the synthesis of pharmaceuticals. It is characterized by its unique molecular structure, which includes a cyclopropylcarbonyl group, a dimethylamino group, and a methyl ester group attached to an acrylic acid backbone. (1-cyclopropyl-methanoyl)-dimethylamino-acrylic acid methyl ester plays a significant role in the development of soluble guanylyl cyclase activators, which are important in the treatment of various medical conditions.

Uses

Used in Pharmaceutical Industry:
(1-cyclopropyl-methanoyl)-dimethylamino-acrylic acid methyl ester is used as an intermediate in the synthesis of soluble guanylyl cyclase activators for the treatment of medical conditions such as pulmonary arterial hypertension, heart failure, and certain types of anemia. Its role in the synthesis process is to provide a structural foundation for the development of these activators, which can modulate the activity of guanylyl cyclase, a key enzyme in the regulation of vascular tone and blood flow.

Upstream product

• 32249-35-7 methyl 3-cyclopropyl-3-oxopropanoate 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 916830-62-1 methyl 1-(1-benzyloxycarbonylpiperidin-4-yl)-5-cyclopropyl-1H-pyrazole-4-carboxylate 
• 1030014-91-5 methyl 5-cyclopropyl-1-(4-fluoro-phenyl)-1H-pyrazole-4-carboxylate 
• 863774-12-3 2-(3-chloro-phenylamino)-4-cyclopropyl-pyrimidine-5-carboxylic acid methyl ester 

Relevant articles and documents

PLASMA KALLIKREIN INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

METHOD FOR PRODUCING PYRROLIDINE COMPOUND

Provided is a method capable of efficiently producing a compound having a superior HSD1 inhibitory action and a compound useful as a synthetic intermediate therefor, with superior achievability of asymmetric synthesis (i.e., superior selectivity), superior yield, superior safety and superior industrial workability at a low cost. A method of producing a compound represented by the following formula [8]: or a salt thereof, or a solvate thereof, from a compound represented by the following formula [2]: or a reactive derivative thereof, or a salt thereof, or a solvate thereof.

3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES

Disclosed compounds of formula (I), which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.